Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Ren Nutr. 2012 Mar;22(2):244-50. doi: 10.1053/j.jrn.2011.06.005. Epub 2011 Sep 10.

Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis.

Author information

  • 1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

OBJECTIVE:

We examined the effects of alpha-lipoic acid (ALA) supplementation on inflammation, oxidative stress, and serum lipid profile levels in hemodialysis (HD) patients.

DESIGN:

This was a double-blinded, randomized, placebo-controlled clinical trial.

SETTING:

The present study involved HD centers in Tabriz, Iran.

PATIENTS:

Participants included 63 patients with end-stage renal disease (43 men and 20 women; age range: 22-79 years) undergoing maintenance HD.

INTERVENTION:

HD patients were randomly assigned into the supplemented group (n = 31), receiving a daily dose of ALA (600 mg), or a control group (n = 32), receiving placebo for 8 weeks.

MAIN OUTCOME MEASURES:

High sensitivity C-reactive protein (hsCRP), malondialdehyde, total antioxidant status, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured at baseline and after 8 weeks of supplementation.

RESULTS:

At the end of intervention, 11 patients were excluded from the study. HsCRP levels decreased by 18.7% in the supplemented group after 8 weeks of supplementation, and the reduction was significant in comparison with the placebo group (P < .05); this finding was also significant after adjusting for baseline values of hsCRP. The mean malondialdehyde and total antioxidant status levels did not change significantly in the 2 groups during the study. The mean high-density lipoprotein cholesterol concentrations increased significantly in the supplemented group at the end of the study (P < .05); however, this improvement was not statistically significant as compared with the placebo group. No significant alterations were observed in the other lipid profile parameters within each group during the study.

CONCLUSION:

ALA supplementation significantly reduced hsCRP levels, which is a risk factor for cardiovascular disease in HD patients.

Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

PMID:
21908204
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk